SIGA's tecovirimat misses primary endpoint in PALM 007 mpox trial; shows benefit in subgroups

SIGA TECHNOLOGIES INC

PALM 007 did not meet primary endpoint of statistically significant improvement in time to lesion resolution.
Tecovirimat showed clinical benefit vs. placebo in patients treated ≤7 days from symptom onset and those with ≥100 lesions.
Safety profile comparable to placebo; consistent with prior studies over 15 years.
Four additional randomized trials (STOMP, UNITY, Platinum-CAN, EPOXI) are ongoing.
Trial hospitalized all patients, which may have reduced measured benefit vs. real-world settings.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.